A thorough review of a company's IP assets may determine whether a business transaction will go forward.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
35 USC §262.
Ethicon, Inc. v. U.S. Surgical Corp., 135 F.3d 1456, 1467-68 (Fed. Cir.), cert. denied, 525 US 923 (1998).
A co-inventor need not make a contribution to every claim of a patent. 35 USC §116.
35 USC §103(c).
Regents University of California v. Genentech Inc. et al., No. 90-CV-2232 (N.D. Ca.).
See Nature 399, 289 (1999).
35 USC §§200–212.
35 USC §154(b).
35 USC §156.
Acknowledgements
The authors are indebted to Carey Miller, whose research contributed to the preparation of this article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gogoris, A., Clarke, P. Patent due diligence in biotechnology transactions. Nat Biotechnol 19, 175–177 (2001). https://doi.org/10.1038/84457
Issue Date:
DOI: https://doi.org/10.1038/84457
This article is cited by
-
Trendspotting: a shift in intellectual property focus
Bioentrepreneur (2006)